N-(coumarin-3-yl)cinnamamide Promotes Immunomodulatory, Neuroprotective, and Lung Function-Preserving Effects during Severe Malaria-Reference-Cited by-同舟云学术

N-(coumarin-3-yl)cinnamamide Promotes Immunomodulatory, Neuroprotective, and Lung Function-Preserving Effects during Severe Malaria

Published:2023-12-27 Issue:1 Volume:17 Page:46
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Gaio Paulo¹^ORCID,Cramer Allysson¹^ORCID,de Melo Oliveira Natália Fernanda¹,Porto Samuel¹,Kramer Lucas¹,Nonato Rabelo Rayane Aparecida¹,Pereira Rafaela das Dores¹,de Oliveira Santos Laura Lis¹,Nascimento Barbosa César Luís²,Silva Oliveira Fabrício Marcus³,Martins Teixeira Mauro¹²^ORCID,Castro Russo Remo⁴^ORCID,Matos Maria João⁵^ORCID,Simão Machado Fabiana¹²

Affiliation:

1. Department of Biochemistry and Immunology, Institute of Biological Science, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

2. Program in Health Sciences, Infectious Diseases and Tropical Medicine/Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil

3. Cellular and Molecular Immunology Group, René Rachou Institute, Oswald o Cruz Foundation—FIOCRUZ, Belo Horizonte 30190-002, MG, Brazil

4. Laboratory of Pulmonary Immunology and Mechanics, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

5. Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

Abstract

Plasmodium berghei ANKA (PbA) infection in mice resembles several aspects of severe malaria in humans, such as cerebral malaria and acute respiratory distress syndrome. Herein, the effects of N-(coumarin-3-yl)cinnamamide (M220) against severe experimental malaria have been investigated. Treatment with M220 proved to protect cognitive abilities and lung function in PbA-infected mice, observed by an object recognition test and spirometry, respectively. In addition, treated mice demonstrated decreased levels of brain and lung inflammation. The production and accumulation of microglia, and immune cells that produce the inflammatory cytokines TNF and IFN-γ, decreased, while the production of the anti-inflammatory cytokine IL-10 by innate and adaptive immune cells was enhanced. Treatment with M220 promotes immunomodulatory, neuroprotective, and lung function-preserving effects during experimental severe malaria. Therefore, it may be an interesting therapeutic candidate to treat severe malaria effects.

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação de Amparo a Pesquisa de Minas Gerais

Rede Mineira de Imunobiológicos

Rede de Investigação em Mucosas e Pele

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Ministerio de Ciencia e Innovación

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/17/1/46/pdf

Reference66 articles.

1. Malaria;Phillips;Nat. Rev. Dis. Primers,2017

2. Severe Malaria: What’s New on the Pathogenesis Front?;Wassmer;Int. J. Parasitol.,2017

3. Experimental Malaria-Associated Acute Respiratory Distress Syndrome Is Dependent on the Parasite-Host Combination and Coincides with Normocyte Invasion;Vandermosten;Malar. J.,2018

4. (2022). World Malaria Report, World Health Organization.

5. Craig, A.G., Grau, G.E., Janse, C., Kazura, J.W., Milner, D., Barnwell, J.W., Turner, G., and Langhorne, J. (2012). The Role of Animal Models for Research on Severe Malaria. PLoS Pathog., 8.